Bonnot PE, Piessen G, Kepenekian V, et al. - Outcomes between cytoreductive surgery (CRS)-hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone (CRSa) among patients with peritoneal metastases (PMs) from gastric cancer (GC) were compared. At 19 French centers, 277 patients with PMs from GC were treated with complete CRS with curative intent (no residual nodules > 2.5 mm) from 1989 to 2014; 180 of these had CRS-HIPEC and had 97 CRSa. Outcomes revealed improved overall survival and recurrence-free survival in correlation with receipt of CRS-HIPEC vs CRSa, with no additional morbidity or mortality. Researchers suggest considering CRS-HIPEC a valuable treatment for strictly selected patients with limited PMs from GC when complete CRS is possible.